Voyager Therapeutics (NASDAQ:VYGR) Stock Price Up 8.1%

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) were up 8.1% during trading on Monday . The stock traded as high as $10.07 and last traded at $10.06. Approximately 147,419 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 992,340 shares. The stock had previously closed at $9.31.

Analyst Ratings Changes

Several brokerages have issued reports on VYGR. Wells Fargo & Company raised shares of Voyager Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $9.00 to $14.00 in a report on Tuesday, January 2nd. Citigroup began coverage on shares of Voyager Therapeutics in a research note on Thursday, March 7th. They set a "buy" rating and a $16.00 price target for the company. Guggenheim started coverage on Voyager Therapeutics in a research note on Tuesday, March 26th. They issued a "buy" rating and a $22.00 price objective on the stock. StockNews.com upgraded Voyager Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, March 9th. Finally, HC Wainwright started coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They issued a "buy" rating and a $30.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $19.33.

Voyager Therapeutics Price Performance

The business's 50 day simple moving average is $8.47 and its 200-day simple moving average is $7.86. The stock has a market capitalization of $572.33 million, a P/E ratio of 3.41 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported $1.25 EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $1.84. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. The business had revenue of $90.06 million during the quarter, compared to the consensus estimate of $4.95 million. Research analysts anticipate that Voyager Therapeutics, Inc. will post -1.64 earnings per share for the current fiscal year.

Institutional Trading of Voyager Therapeutics

Hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new position in Voyager Therapeutics during the second quarter valued at approximately $30,000. Gladius Capital Management LP bought a new stake in shares of Voyager Therapeutics in the 3rd quarter valued at $25,000. AJOVista LLC acquired a new stake in Voyager Therapeutics during the 4th quarter worth $39,000. UBS Group AG acquired a new stake in Voyager Therapeutics during the 1st quarter worth $39,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Voyager Therapeutics during the fourth quarter worth about $43,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.